Briacell, MSK to work on Bria-OTS+ clinical development

Executive Summary

• Briacell Therapeutics Corp. has entered into a collaboration with Memorial Sloan Kettering Cancer Center’s (MSK) therapeutics accelerator cohort program to advance the clinical development of its next-generation personalized off-the-shelf immunotherapy platform, Bria-OTS+.
• The initial phase of the collaboration focuses on manufacturing, Investigational New Drug (IND) development, and clinical protocol support for a Phase 1 clinical trial of Bria-BRES+, a specific immunotherapy for breast cancer under the Bria-OTS+ platform.
• This partnership builds upon Briacell’s previously announced selection into the MSK accelerator program, granting access to MSK’s clinical and institutional expertise to expedite the development of the Bria-OTS+ platform for multiple cancer indications, including metastatic breast cancer and prostate cancer.

Key Details

• Collaboration Partner: Memorial Sloan Kettering Cancer Center (MSK) via its therapeutics accelerator program.
• Core Technology: Bria-OTS+, described as a next-generation personalized off-the-shelf immunotherapy platform.
• Target Indications: Metastatic breast cancer, prostate cancer, and other cancers.
• Initial Scope: Manufacturing, IND development, and clinical protocol support for a Phase 1 clinical trial.
• Specific Asset: The collaboration begins with Bria-BRES+, Briacell’s next-generation personalized immunotherapy for patients with breast cancer.
• Strategic Benefit: Access to MSK’s clinical and institutional expertise, including cell therapy manufacturing, IND preparation, submission, and clinical development.
• Institutional Interest: MSK holds institutional financial interests related to Briacell.

Notable Quotes

• Dr. William V. Williams, President and CEO, Briacell: "We are thrilled to collaborate with MSK's scientific and clinical experts to address the urgent unmet medical need of many thousands of metastatic breast cancer patients."
• Dr. Miguel Lopez-Lago, PhD, Chief Scientific Officer, Briacell: "We are honoured to be working with the team of cancer specialists at MSK... This collaboration with MSK will accelerate the development of our advanced personalized off-the-shelf immunotherapy platform, Bria-OTS+, which we believe has the potential to transform cancer care and significantly improve patients' lives through its unique mechanism of action."
• Dr. Shanu Modi, MD, Breast Medical Oncologist at MSK: "We look forward to working with Briacell through MSK's therapeutics accelerator to help advance this next-generation personalized immunotherapy into the clinic. Collaborations like this are essential to translating promising scientific innovations into potential new treatment options for patients."